share_log

Ocugen's Partner COVID-19 Vaccine Covaxin Shows Encouraging Action In Children Below 18 Years

Ocugen's Partner COVID-19 Vaccine Covaxin Shows Encouraging Action In Children Below 18 Years

欧库根公司的合作伙伴新冠肺炎疫苗柯瓦辛在18岁以下儿童中表现出令人鼓舞的行动
Benzinga Real-time News ·  2022/06/21 22:25
  • $Ocugen(OCGN.US)$ announced the publication of positive pediatric Phase 2/3 study results in children aged 2–18 years for COVID-19 vaccine, Covaxin (BBV152), in The Lancet Infectious Diseases.

  • Covaxin is developed and manufactured by Ocugen's India-based partner Bharat Biotech International Limited. 

  • It is under clinical investigation by Ocugen in the U.S. for use in adults aged 18 years and older.

  • Related: FDA Removes Clinical Hold On Ocugen's COVID Vaccine Trial.

  • The low reactogenicity can potentially make Covaxin more acceptable in pediatric populations than the more reactogenic mRNA vaccines.

  • Bharat Biotech's pediatric Phase 2/3 study showed no serious adverse events, deaths, or withdrawals due to an adverse event, including no cases of Guillain-Barré syndrome, thromboembolic events, myocarditis, pericarditis, or other adverse events of particular interest being observed to date. 

  • Data comes from 526 children. Local reactions mainly consisted of mild injection site pain.

  • Geometric mean titers of microneutralization antibodies at day 56 were similar to titers in vaccinated adults. 

  • Price Action: OCGN shares are up 4.63% at $2.26 during the market session on the last check Tuesday.

  • $Ocugen(OCGN.US)$ 宣布在《柳叶刀传染病》杂志上发表新冠肺炎疫苗Covaxin(BBV152)在2-18岁儿童中的儿科2/3期阳性研究结果。

  • Covaxin是由Ocugen的印度合作伙伴Bharat Biotech International Limited开发和制造的。

  • 它正在由美国Ocugen公司进行临床研究,用于18岁及以上的成年人。

  • 相关: FDA取消Ocugen的COVID疫苗试验的临床搁置.

  • 与更具反应性的mRNA疫苗相比,低反应性可能会使Covaxin更容易被儿科人群接受。

  • Bharat Biotech的儿科2/3期研究显示,到目前为止,没有观察到严重的不良事件、死亡或因不良事件导致的停药,包括格林-巴利综合征、血栓栓子事件、心肌炎、心包炎或其他特别感兴趣的不良事件。

  • 数据来自526名儿童。局部反应主要表现为注射部位轻度疼痛。

  • 在第56天,微量中和抗体的几何平均滴度与接种疫苗的成人相似。

  • 价格行动:周二尾盘,OCGN股价上涨4.63%,至2.26美元。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发